Mahidol University's Institutional Repository (Mahidol IR): Browsing DSpace

Simple jQuery Dropdowns

Browsing by Author Samruay Nilkamhang

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:

Showing results 1 to 14 of 14

Issue Date	Title	Author(s)
1-Jan-2014	ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen	Weerawat Manosuthi; Chonlaphat Sukasem; Supeda Thongyen; Samruay Nilkamhang; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University
1-Jan-2015	Comparison of thai government manufactured tenofovir (Tenofovir GPO300) with privately manufactured tenofovir (Viread) used along with lamivudine and efavirenz to treat Thai HIV patients	Weerawat Manosuthi; Supeda Thongyen; Samruay Nilkamhang; Sukanya Manosuthi; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University
1-Jan-2014	CYP2B6 18492T→C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype 1/1	Weerawat Manosuthi; Chonlaphat Sukasem; Suped Thongyen; Samruay Nilkamhang; Sukanya Manosuthi; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University
1-Jan-2014	CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy	Weerawat Manosuthi; Chonlaphat Sukasem; Aroon Lueangniyomkul; Wiroj Mankatitham; Supeda Thongyen; Samruay Nilkamhang; Sukanya Manosuthi; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University
1-Feb-2013	HIV-1 drug resistance-associated mutations among antiretroviral-naive thai patients with chronic HIV-1 infection	Weerawat Manosuthi; Supeda Thongyen; Samruay Nilkamhang; Sukanya Manosuthi; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University
1-Feb-2013	Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients	Weerawat Manosuthi; Chonlaphat Sukasem; Aroon Lueangniyomkul; Wiroj Mankatitham; Supeda Thongyen; Samruay Nilkamhang; Sukanya Manosuthi; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University
13-Mar-2012	Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure	Weerawat Manosuthi; Supeda Thongyen; Samruay Nilkamhang; Sukanya Manosuthi; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University
1-May-2011	Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: A prospective study	Weerawat Manosuthi; Aroon Lueangniyomkul; Wiroj Mankatitham; Sukanya Chimsuntorn; Preecha Tantanathip; Supeda Thongyen; Busakorn Suntisuklappon; Samruay Nilkamhang; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University
11-Oct-2010	Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens	Weerawat Manosuthi; Wiroj Mankatitham; Aroon Lueangniyomkul; Wisit Prasithsirikul; Preecha Tantanathip; Busakorn Suntisuklappon; Anongnuch Narkksoksung; Samruay Nilkamhang; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University
8-Aug-2011	Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting	Weerawat Manosuthi; Wisit Prasithsirikul; Preecha Tantanathip; Sukanya Chimsuntorn; Samruay Nilkamhang; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University
1-Mar-2011	Single-boosted protease inhibitor versus double-boosted protease inhibitors for the salvage therapy in HIV-infected patients	Weerawat Manosuthi; Sukanya Chimsuntorn; Supeda Thongyen; Samruay Nilkamhang; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University; Bamrasnaradura Infectious Diseases Institute
1-Aug-2012	Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: Results From the TIME study	Weerawat Manosuthi; Wiroj Mankatitham; Aroon Lueangniyomkul; Supeda Thongyen; Sirirat Likanonsakul; Pawita Suwanvattana; Unchana Thawornwan; Busakorn Suntisuklappon; Samruay Nilkamhang; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University
23-Dec-2009	Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure	Weerawat Manosuthi; Sasisopin Kiertiburanakul; Wannarat Amornnimit; Wisit Prasithsirikul; Supeda Thongyen; Samruay Nilkamhang; Kiat Ruxrungtham; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University; The HIV Netherlands Australia Thailand Research Collaboration; Chulalongkorn University
1-Nov-2010	Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: A four-year prospective study	Weerawat Manosuthi; Preecha Tantanathip; Sukanya Chimsuntorn; Boonchuay Eampokarap; Supeda Thongyen; Samruay Nilkamhang; Somnuek Sungkanuparph; Thailand Ministry of Public Health; Mahidol University

Showing results 1 to 14 of 14